Search

Your search keyword '"Girolamo Pelaia, MD"' showing total 3 results
Start Over Author "Girolamo Pelaia, MD"
3 results on '"Girolamo Pelaia, MD"'

1. Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)

Author

Giorgio Walter Canonica, MD, Francesco Blasi, PhD, Pierluigi Paggiaro, MD, Enrico Heffler, PhD, Fulvio Braido, MD, Luisa Brussino, PhD, Giulia Scioscia, PhD, Cristina Cardini, MsC, Chiara Oriecuia, MsC, Isabella Sala, MsC, Vincenzo Bagnardi, PhD, Cecilia Calabrese, PhD, Gianna Camiciottoli, MD, Giovanna Elisiana Carpagnano, PhD, Stefano Centanni, PhD, Angelo Guido Corsico, PhD, Maria Teresa Costantino, MD, Claudia Crimi, PhD, Alice D'Adda, MD, Simona D’Alò, MD, Maria D'Amato, PhD, Corrado D'Andria, MD, Stefano Del Giacco, MD, Fabiano Di Marco, PhD, Nicola Cosimo Facciolongo, MD, Alessandro Farsi, MD, Manuela Latorre, PhD, Manlio Milanese, PhD, Eustachio Nettis, MD, Eleonora Nucera, MD, Giovanni Passalacqua, MD, Girolamo Pelaia, MD, Laura Pini, MD, Luisa Ricciardi, PhD, Fabio Luigi Massimo Ricciardolo, PhD, Luca Richeldi, PhD, Erminia Ridolo, PhD, Pierachille Santus, PhD, Nicola Scichilone, PhD, Gianenrico Senna, MD, Giuseppe Spadaro, MD, Antonio Spanevello, MD, and Paolo Tarsia, MD

Subjects
Severe asthma, Clinical remission, Inhaled therapy, Biologics, Registry, Immunologic diseases. Allergy, RC581-607
Abstract

Background: This study aimed to evaluate the impact of severe asthma (SA) treatments after 12 months in achieving clinical remission (CR) within the context of the Severe Asthma Network in Italy (SANI) using the recent SANI definition of CR on treatment. Methods: CR has been defined by SANI as complete, partial, and no CR. Complete CR is defined by the absence of oral corticosteroids (OCS), no symptoms, no exacerbations, and stable lung function, and partial CR requires the absence of OCS and the fulfillment of 2 out of the other 3 criteria. Patients who do not meet the previous criteria do not reach CR. Results: After 12 months of treatment, 283 patients were selected to evaluate the effectiveness of biologics (225 patients) and inhaled therapy (58 patients) in achieving CR. Among patients treated with biologic agents, 45.8% reached complete CR, 23.1% partial CR, and 31.1% no CR. Differences in CR achievement according to type of biologic agent administered were observed. Interesting results were found when assessing the inhaled therapy (ICS/LABA/LAMA and no biologics) effectiveness: 34.5% patients reached complete CR, 34.5% partial CR, and 31.0% did not reach CR. This finding is noteworthy since it further supports the efficacy of inhaled treatment in certain SA patients and highlights the relevance of using CR as a modern outcome of SA treatments. Chronic rhinosinusitis with nasal polyps (CRSwNP) comorbidity was associated, though not significantly, with CR achievement in patients treated with biologics. Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ) scores significantly impacted CR (p = 0.003 and p = 0.027, respectively), while biomarkers, namely IgE, blood eosinophils, or fractional exhaled nitric oxide (FeNO), were not associated with CR achievement. Conclusions: This study confirmed the effectiveness of biologics in reaching CR and demonstrated also inhaled therapies able to achieve CR. These innovative findings should encourage post hoc analysis of randomized clinical trials or even retrospective analysis of SA patient cohorts to evaluate CR with different inhaled treatments and further define the populations eligible for each treatment. Trial registration: ClinicalTrials.gov ID: NCT06625216; Central Ethics Committee: Comitato Etico Area Vasta Nord-Ovest Toscana (study number 1245/2016, protocol number:73714).

Published
2025
Full Text
View/download PDF

2. Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort

Author

Marco Caminati, MD, Alessandro Marcon, PhD, Rachele Vaia, MD, Gianenrico Senna, MD, Matteo Maule, MD, Pierpaolo Marchetti, MD, Jessica Miotti, MD, Giuseppe Argentino, MD, Francesco Blasi, MD, PhD, Giorgio W. Canonica, MD, Enrico M. Heffler, MD, PhD, Pierluigi Paggiaro, MD, Andrea Vianello, MD, PhD, Gabriella Guarnieri, MD, Luisa Brussino, MD PhD, S.S.D.D.U, Cecilia Calabrese, MD PhD, Gianna Camiciottoli, MD, Giovanna E. Carpagnano, MD PhD, Stefano Centanni, MD PhD, Angelo G. Corsico, MD PhD, Maria T. Costantino, MD, Claudia Crimi, MD PhD, Alice D'adda, MD, Simona D'alo, MD, Maria D'amato, MD PhD, Stefano Del Giacco, MD, Fabiano Di Marco, MD PhD, Nicola C. Facciolongo, MD, Manuela Latorre, MD PhD, Eustachio Nettis, MD, Eleonora Nucera, MD, Giovanni Passalacqua, MD, Girolamo Pelaia, MD, Laura Pini, MD PhD, Luisa Ricciardi, MD, Luca Richeldi, MD, Erminia Ridolo, MD PhD, Pierachille Santus, MD PhD, Nicola Scichilone, MD, Giulia Scioscia, MD PhD, Giuseppe Spadaro, MD, Antonio Spanevello, MD PhD, and Paolo Tarsia, MD PhD

Subjects
Severe asthma, Aging, Comorbidities, Lung function, Asthma control, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Aging implies changes in terms of lung function, immune system, and respiratory and extra-respiratory comorbidities. Few studies have specifically addressed the relevance of age on severe asthma burden and control. We aimed to evaluate whether age acts as an independent determinant of asthma severity, in terms of clinical, functional, and inflammatory profile, and to explore potential cofactors that contribute to a more difficult disease control in different age groups. Methods: Patients from Severe Asthma Network Italy (SANI) registry were retrospectively divided in subgroups according to their age. Cutoffs for age were established according to quartiles in order to obtain a comparable number of patients for each group, and then rounded for the sake of simplicity. Results: Overall, 1805 severe asthma patients were analyzed. Lung function represented the most important age-related variable. On the opposite the level of asthma control was not differently distributed among age ranges. In young people the presence of atopy-related comorbidities (allergic rhinitis, atopic dermatitis) predominated, whilst systemic-metabolic and degenerative comorbidities such as diabetes, cardiovascular diseases, anxious-depressive syndrome, and osteoporosis prevailed in elderly. Bronchiectasis and sleep disturbances were significantly associated with age. Conclusions: Despite that it cannot be considered a treatable trait, our study suggests that age should be evaluated within a personalized approach to severe asthma patients, in order to provide a better clinical profiling and a more tailored treatment strategy.

Published
2024
Full Text
View/download PDF

3. Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Author

Diego Bagnasco, MD, PhD, Rikki Frank Canevari, MD, Stefano Del Giacco, MD, Silvia Ferrucci, MD, Paolo Pigatto, MD, Paolo Castelnuovo, MD, Gian Luigi Marseglia, MD, Arzu Didem Yalcin, MD, Girolamo Pelaia, MD, and Giorgio Walter Canonica, MD

Subjects
Severe asthma, Omalizumab, Cancer, Anti IgE, Monoclonal antibodies, Immunologic diseases. Allergy, RC581-607
Abstract

Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has been recently linked to potential increased cancer risk. Nevertheless, literature evidence does not support this statement, and clinical studies and evidence from real-world registries and surveillance analysis have consistently reported drug safety.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results